NMT1 and breast ductal adenocarcinoma: Using the OncolinesTM robotic drug testing platform three breast carcinoma (BT-20, DU4475, and Hs 578 T), one breast ductal carcinoma (BT-549), and two breast adenocarcinoma cell lines (AU-565, MCF7) were treated with increasing concentrations (3.16–31,600 nM) of the pan-NMT inhibitor PCLX-001 for 72hrs, which allowed us to calculate IC50, GI50, and LD50 values (Table 3).